Oruka Therapeutics
Most recent annual filing: 2026-03-12
- ORKA-001 readout4Q 2026ORKA-001 readout, 4Q 2026, material
- ORKA-004 corporate update4Q 2026ORKA-004 corporate update, 4Q 2026, routine
- ORKA-001 Ph3 topline2027ORKA-001 Ph3 topline, 2027, major
- ORKA-002 Ph2 topline2027ORKA-002 Ph2 topline, 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
Technology platforms
Hypercon · Halozyme
Halozyme's Hypercon microparticle technology enabling hyperconcentration of drugs and biologics to reduce injection volume and support patient-friendly administration; licensed by Oruka for IL-23p19 in psoriatic disease and up to one additional target
Targets: IL-23p19
Biotech Distilled coverage (4)
- 2026-08-11 UPDATE: Oruka Therapeutics (ORKA) - Four Readouts Before the Snow Melts 🔒 Paid
- 2026-07-02 UPDATE: Oruka Therapeutics (ORKA) - Fairmount Takes Chips Off the Table 🔒 Paid
- 2026-06-02 UPDATE: Oruka Therapeutics (ORKA) - The IBD Door Opens 🔒 Paid
- 2026-05-13 Oruka Therapeutics (ORKA) - Scientific Deep Dive for ORKA-001, ORKA-002, and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.